



**INDOCO REMEDIES LIMITED**

Regd. Office : Indoco House, 166, CST Road, Kalina, Santacruz (E), Mumbai 400 098

Tel: +91-22-26541851/55 Fax: +91-22-26520787 Email: compliance.officer@indoco.com

Website: www.indoco.com CIN: L85190MH1947PLC005913

**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2018**

(₹ In Lakhs)

Sr. No	Particulars	Quarter ended 31.12.2018 (Unaudited)	Quarter ended 30.09.2018 (Unaudited)	Quarter ended 31.12.2017 (Unaudited)	Nine months ended 31.12.2018 (Unaudited)	Nine months ended 31.12.2017 (Unaudited)	Year ended 31.03.2018 (Audited)
1	<b>Income from Operations</b>						
	(a) Revenue from Operations	24,800	23,591	27,419	69,640	75,845	1,01,731
	(b) Other Operating Income	1,456	(28)	393	1,932	1,349	2,427
	<b>Total Income from Operations (Net) (a+b)</b>	<b>26,256</b>	<b>23,563</b>	<b>27,812</b>	<b>71,572</b>	<b>77,194</b>	<b>1,04,158</b>
2	<b>Other Income</b>	57	33	55	121	375	479
3	<b>Total Income (1+2)</b>	<b>26,313</b>	<b>23,596</b>	<b>27,867</b>	<b>71,693</b>	<b>77,569</b>	<b>1,04,637</b>
4	<b>Expenses</b>						
	(a) Cost of materials consumed	6,916	5,464	7,020	17,218	20,628	28,149
	(b) Purchases of stock-in-trade	1,730	2,143	1,779	5,583	5,063	6,460
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	176	355	250	1,112	494	330
	(d) Employee Benefits Expense	5,889	5,848	5,790	17,347	16,957	22,034
	(e) Research & Development Expense	1,244	1,275	1,439	3,840	3,971	5,349
	(f) Other Expenses	7,823	7,297	7,213	21,656	21,538	28,350
	(g) Finance Costs	372	501	212	1,591	1,518	2,351
	(h) Depreciation and Amortisation Expense	1,773	1,765	1,730	5,210	5,138	6,771
	<b>Total Expenses</b>	<b>25,923</b>	<b>24,648</b>	<b>25,433</b>	<b>73,557</b>	<b>75,307</b>	<b>99,794</b>
5	<b>Profit/(Loss) before Tax (3-4)</b>	<b>390</b>	<b>(1,052)</b>	<b>2,434</b>	<b>(1,864)</b>	<b>2,262</b>	<b>4,843</b>
6	<b>Tax Expenses - Current</b>	-	-	464	-	464	1,107
	- Deferred	26	(522)	(710)	(496)	(685)	(1,006)
	- MAT Credit Adjustments	(170)	249	414	79	414	622
	<b>Total Tax Expenses</b>	<b>(144)</b>	<b>(273)</b>	<b>168</b>	<b>(417)</b>	<b>193</b>	<b>723</b>
7	<b>Profit/(Loss) for the period (5-6)</b>	<b>534</b>	<b>(779)</b>	<b>2,266</b>	<b>(1,447)</b>	<b>2,069</b>	<b>4,120</b>
8	<b>Other Comprehensive Income</b>						
a	i) Items that will not be reclassified to profit and loss	(3)	(3)	(4)	(9)	(14)	35
	ii) Income tax on relating to this item	1	1	2	3	5	(12)
b	i) Items that may be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total Other Comprehensive Income</b>	<b>(2)</b>	<b>(2)</b>	<b>(2)</b>	<b>(6)</b>	<b>(9)</b>	<b>23</b>
9	<b>Total Comprehensive income for the year (7+8)</b>	<b>532</b>	<b>(781)</b>	<b>2,264</b>	<b>(1,453)</b>	<b>2,060</b>	<b>4,143</b>
10	Paid up Equity Share Capital (Face value ₹ 2/- each)	1,843	1,843	1,843	1,843	1,843	1,843
11	Other Equity	-	-	-	-	-	65,713
12	Earnings per share (of ₹ 2/- each)						
	(a) Basic- in ₹	0.58	(0.85)	2.46	(1.57)	2.25	4.47
	(b) Diluted- in ₹	0.58	(0.85)	2.46	(1.57)	2.25	4.47

**Notes :**

1 Above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 23rd January, 2019.

2 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(₹ In Lakhs)

Net Sales and Income from Operations	Quarter ended 31.12.2018 (Unaudited)	Quarter ended 30.09.2018 (Unaudited)	Quarter ended 31.12.2017 (Unaudited)	Nine months ended 31.12.2018 (Unaudited)	Nine months ended 31.12.2017 (Unaudited)	Year ended 31.03.2018 (Audited)
India	16,448	16,948	16,347	49,755	47,118	63,335
Outside India	8,352	6,643	11,072	19,885	28,727	38,396
<b>Total</b>	<b>24,800</b>	<b>23,591</b>	<b>27,419</b>	<b>69,640</b>	<b>75,845</b>	<b>1,01,731</b>

3 The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 31st December, 2018.

4 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

By Order of the Board  
For Indoco Remedies Ltd

s/d

Suresh G. Kare

Chairman

Place : Mumbai

Date : 23rd January, 2019